Finally, the ASCO/CAP 2013 recommendations also address the issue of HER2 heterogeneity [8], which was defined as a separate population of HER2-positive or ISH-positive tumor cells representing at least 10% of the entire neoplastic cell population. This evidence concerns the gene ERBB2 and neoplasm.